AU5750490A - Creation of Inventions and Patents with Artificial Intelligence

AU5750490A – Production of erythropoietin
– Google Patents

AU5750490A – Production of erythropoietin
– Google Patents
Production of erythropoietin

Info

Publication number
AU5750490A

AU5750490A
AU57504/90A
AU5750490A
AU5750490A
AU 5750490 A
AU5750490 A
AU 5750490A
AU 57504/90 A
AU57504/90 A
AU 57504/90A
AU 5750490 A
AU5750490 A
AU 5750490A
AU 5750490 A
AU5750490 A
AU 5750490A
Authority
AU
Australia
Prior art keywords
erythropoietin
production
Prior art date
1983-12-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU57504/90A
Inventor
Fu-Kuen Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen K A Inc

Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1983-12-13
Filing date
1990-06-15
Publication date
1990-10-04
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=27504819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU5750490(A)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1984-11-30
Priority claimed from US06/675,298
external-priority
patent/US4703008A/en

1990-06-15
Application filed by Kirin Amgen Inc
filed
Critical
Kirin Amgen Inc

1990-10-04
Publication of AU5750490A
publication
Critical
patent/AU5750490A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P7/00—Drugs for disorders of the blood or the extracellular fluid

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P7/00—Drugs for disorders of the blood or the extracellular fluid

A61P7/06—Antianaemics

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/475—Growth factors; Growth regulators

C07K14/505—Erythropoietin [EPO]

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/70—Vectors or expression systems specially adapted for E. coli

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi

C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2800/00—Nucleic acids vectors

C12N2800/10—Plasmid DNA

C12N2800/108—Plasmid DNA episomal vectors

AU57504/90A
1983-12-13
1990-06-15
Production of erythropoietin

Abandoned

AU5750490A
(en)

Applications Claiming Priority (8)

Application Number
Priority Date
Filing Date
Title

US56102483A

1983-12-13
1983-12-13

US561024

1983-12-13

US58218584A

1984-02-21
1984-02-21

US582185

1984-02-21

US65584184A

1984-09-28
1984-09-28

US655841

1984-09-28

US06/675,298

US4703008A
(en)

1983-12-13
1984-11-30
DNA sequences encoding erythropoietin

US675298

1984-11-30

Related Parent Applications (1)

Application Number
Title
Priority Date
Filing Date

AU37467/85A
Division

AU600650C
(en)

1983-12-13
1984-12-11
Polypeptides of erythropoietin

Related Child Applications (2)

Application Number
Title
Priority Date
Filing Date

AU20421/92A
Division

AU657555B2
(en)

1983-12-13
1992-07-20
Production of erythropoietin

AU52722/93A
Division

AU5272293A
(en)

1983-12-13
1993-12-23
Production of erythropoietin

Publications (1)

Publication Number
Publication Date

AU5750490A
true

AU5750490A
(en)

1990-10-04

Family
ID=27504819
Family Applications (5)

Application Number
Title
Priority Date
Filing Date

AU57504/90A
Abandoned

AU5750490A
(en)

1983-12-13
1990-06-15
Production of erythropoietin

AU20421/92A
Expired

AU657555B2
(en)

1983-12-13
1992-07-20
Production of erythropoietin

AU52722/93A
Abandoned

AU5272293A
(en)

1983-12-13
1993-12-23
Production of erythropoietin

AU10074/95A
Abandoned

AU1007495A
(en)

1983-12-13
1995-01-06
Production of erythropoietin

AU36125/97A
Abandoned

AU3612597A
(en)

1983-12-13
1997-08-29
Production of erythropoietin

Family Applications After (4)

Application Number
Title
Priority Date
Filing Date

AU20421/92A
Expired

AU657555B2
(en)

1983-12-13
1992-07-20
Production of erythropoietin

AU52722/93A
Abandoned

AU5272293A
(en)

1983-12-13
1993-12-23
Production of erythropoietin

AU10074/95A
Abandoned

AU1007495A
(en)

1983-12-13
1995-01-06
Production of erythropoietin

AU36125/97A
Abandoned

AU3612597A
(en)

1983-12-13
1997-08-29
Production of erythropoietin

Country Status (15)

Country
Link

US
(3)

US5441868A
(en)

EP
(1)

EP0148605B2
(en)

JP
(9)

JPH0655136B2
(en)

AU
(5)

AU5750490A
(en)

CA
(1)

CA1339047C
(en)

CY
(1)

CY1643A
(en)

DE
(1)

DE3482828D1
(en)

ES
(1)

ES8802329A1
(en)

HK
(1)

HK20093A
(en)

IL
(1)

IL73785A
(en)

MX
(1)

MX9203598A
(en)

NL
(1)

NL930128I1
(en)

NZ
(1)

NZ210501A
(en)

SG
(1)

SG92891G
(en)

WO
(1)

WO1985002610A1
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU646822B2
(en)

1989-10-13
1994-03-10
Kirin-Amgen Inc.
Erythropoietin isoforms

Families Citing this family (353)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

ATE56471T1
(en)

1980-04-03
1990-09-15
Biogen Inc

DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND METHODS OF PRODUCTION OF HUMAN FIBROBLAST INTERFERON.

IT1185503B
(en)

1984-01-11
1987-11-12
Univ New York

HUMAN Erythropietine ODNA CLONES

IL77081A
(en)

1984-12-04
1999-10-28
Genetics Inst
Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin

JPS62501010A
(en)

1984-12-04
1987-04-23
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド

Production method of erythropoietin

US4677195A
(en)

1985-01-11
1987-06-30
Genetics Institute, Inc.
Method for the purification of erythropoietin and erythropoietin compositions

US4732889A
(en)

1985-02-06
1988-03-22
Chugai Seiyaku Kabushiki Kaisha
Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis

US4745099A
(en)

1985-02-06
1988-05-17
Chugai Seiyaku Kabushiki Kaisha
Pharmaceutical composition for the treatment of the anemia of malignant tumors

GB2177914B
(en)

1985-06-04
1989-10-25
Chugai Pharmaceutical Co Ltd
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia

IL79176A
(en)

1985-06-20
1992-06-21
Kirin Amgen Inc
Process for the recovery of erythropoietin from a fluid

US6004548A
(en)

1985-08-23
1999-12-21
Amgen, Inc.
Analogs of pluripotent granulocyte colony-stimulating factor

JPS63500636A
(en)

1985-08-23
1988-03-10
麒麟麦酒株式会社

DNA encoding multipotent granulocyte colony stimulating factor

US4810643A
(en)

1985-08-23
1989-03-07
Kirin- Amgen Inc.
Production of pluripotent granulocyte colony-stimulating factor

US4935350A
(en)

1985-11-18
1990-06-19
Amgen
Materials and methods for controlling plasmid copy number and stability

JPS62171696A
(en)

1986-01-23
1987-07-28
Sumitomo Chem Co Ltd
Production of human erythropoietin

DE3789678T2
(en)

1986-02-27
1994-08-11
Snow Brand Milk Prod Co Ltd

Production of erythropoietin-producing cells and method for producing erythropoietin using these cells.

DK173067B1
(en)

1986-06-27
1999-12-13
Univ Washington

Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines

GR871029B
(en)

1986-07-14
1987-11-02
Genetics Inst
Novel osteoinductive factors

US4954437A
(en)

1986-09-15
1990-09-04
Integrated Genetics, Inc.
Cell encoding recombinant human erythropoietin

US5013718A
(en)

1986-11-21
1991-05-07
Amgen, Inc.
Method for treating iron overload using EPO

WO1988005466A2
(en)

1987-01-15
1988-07-28
Codon
Tandem gene eukaryotic expression vectors

US4835260A
(en)

1987-03-20
1989-05-30
Genetics Institute, Inc.
Erythropoietin composition

JP2791418B2
(en)

1987-12-02
1998-08-27
株式会社ミドリ十字

Method for producing heterologous protein, recombinant DNA, transformant

DE3923963A1
(en)

1989-07-20
1991-01-31
Behringwerke Ag

MUTEINE OF HUMAN ERYTHROPOETIN, THEIR PRODUCTION AND THEIR USE

DE3924746A1
(en)

1989-07-26
1991-01-31
Behringwerke Ag

ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR

US6932968B1
(en)

1989-07-26
2005-08-23
Dade Behring Marburg Gmbh
Erythropoietin (EPO) peptides and antibodies directed against these

US7217689B1
(en)

1989-10-13
2007-05-15
Amgen Inc.
Glycosylation analogs of erythropoietin

DE4115722A1
(en)

1991-05-14
1992-11-19
Boehringer Mannheim Gmbh

SERUM-FREE MEDIUM FOR CULTIVATING SUGAR CELLS

US6270989B1
(en)

1991-11-05
2001-08-07
Transkaryotic Therapies, Inc.
Protein production and delivery

US5968502A
(en)

1991-11-05
1999-10-19
Transkaryotic Therapies, Inc.
Protein production and protein delivery

NZ245015A
(en)

1991-11-05
1995-12-21
Transkaryotic Therapies Inc
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production

US5728536A
(en)

1993-07-29
1998-03-17
St. Jude Children’s Research Hospital
Jak kinases and regulation of Cytokine signal transduction

FR2686899B1
(en)

1992-01-31
1995-09-01
Rhone Poulenc Rorer Sa

NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

US6670178B1
(en)

1992-07-10
2003-12-30
Transkaryotic Therapies, Inc.
In Vivo production and delivery of insulinotropin for gene therapy

US6531124B1
(en)

1992-07-10
2003-03-11
Transkaryotic Therapies, Inc.
In vivo production and delivery of insulinotropin for gene therapy

EP0659759B1
(en)

1992-09-09
1999-12-08
Nippon Kayaku Kabushiki Kaisha
Novel physiologically active substance nk175203, process for producing the same, and pharmaceutical use thereof

WO1994024160A2
(en)

1993-04-21
1994-10-27
Brigham And Women’s Hospital
Erythropoietin muteins with enhanced activity

IL110669A
(en)

1993-08-17
2008-11-26
Kirin Amgen Inc
Erythropoietin analogs

US8192955B1
(en)

1994-01-03
2012-06-05
Genentech, Inc.
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof

US5888774A
(en)

1994-12-19
1999-03-30
Cangene Corporation
Recombinant DNA molecules and expression vectors for erythropoietin

IL118201A
(en)

1995-05-11
2004-12-15
Roche Diagnostics Gmbh
Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

CA2223833C
(en)

1995-06-07
2010-12-21
Nicholas C. Wrighton
Compounds and peptides that bind to the erythropoietin receptor

SI0833934T2
(en)

1995-06-15
2013-04-30
Crucell Holland B.V.
Packaging systems for human recombinant adenovirus to be used in gene therapy

EP0752474A1
(en)

1995-07-07
1997-01-08
Boehringer Mannheim Gmbh
Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins

WO1997003200A1
(en)

1995-07-07
1997-01-30
Boehringer Mannheim Gmbh
Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins

ATE247667T1
(en)

1996-03-14
2003-09-15
Genentech Inc

GDNF RECEPTOR AND ITS USE

GB2318352A
(en)

1996-06-25
1998-04-22
Dejan Markovic
Polypeptides mimicking the activity of human erythropoietin

US5952226A
(en)

1996-11-05
1999-09-14
Modex Therapeutiques
Hypoxia responsive EPO producing cells

US6573055B2
(en)

1997-04-21
2003-06-03
Glycozyme, Inc.
Determination of recombinant glycosylated proteins and peptides in biological fluids

US6475725B1
(en)

1997-06-20
2002-11-05
Baxter Aktiengesellschaft
Recombinant cell clones having increased stability and methods of making and using the same

DE19729769A1
(en)

1997-07-11
1999-01-14
Cardiogene Gentherapeutische S

Transfection system, its manufacture and use in somatic gene therapy

US6017876A
(en)

1997-08-15
2000-01-25
Amgen Inc.
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity

US6897066B1
(en)

1997-09-26
2005-05-24
Athersys, Inc.
Compositions and methods for non-targeted activation of endogenous genes

US7316923B1
(en)

1997-09-26
2008-01-08
Athersys, Inc.
Compositions and methods for non-targeted activation of endogenous genes

IL135604A0
(en)

1997-10-16
2001-05-20
Univ Georgia
Vectors comprising a magnum-specific promoter for avian transgenesis

DK1037927T3
(en)

1997-12-08
2004-09-06
Emd Lexigen Res Ct Corp

Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation

BR9908096A
(en)

1998-02-19
2000-10-31
Eastern Virginia Med School

Recombinant, active, human skin zone protein (hzp3) 3

US7037663B2
(en)

1998-02-19
2006-05-02
Eastern Virginia Medical School
Human zona pellucida protein 3 and uses thereof

SI0937456T1
(en)

1998-02-23
2004-12-31
Cilag Ag International
Erythropoietin liposomal dispersion

US20030105294A1
(en)

1998-02-25
2003-06-05
Stephen Gillies
Enhancing the circulating half life of antibody-based fusion proteins

KR100434729B1
(en)

1998-03-18
2004-11-03
주식회사 엘지생명과학
Method for improving production yield of erythropoietin from chinese hamster ovary(cho) by adding natural extracts in serum free medium, while reducing production cost

WO1999050432A1
(en)

1998-03-27
1999-10-07
Cytos Biotechnology Ag
Inducible alphaviral gene expression system

AR019025A1
(en)

1998-04-09
2001-12-26
Roche Diagnostics Gmbh

USE OF ERYTHROPOYETIN IN LOW DOSE TO PRODUCE A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEMOCROMATOSIS, COMBINED PHARMACEUTICAL PREPARATION USED ACCORDING TO SUCH USE AND PHARMACEUTICAL UNIT PACKAGING CONTAINING THE PHARMACEUTICAL COMBINED PREPARED REFERENCE

ATE329622T1
(en)

1998-04-15
2006-07-15
Lexigen Pharm Corp

ENHANCEMENT OF ANTIBODY-CYTOKINE-FUSION PROTEIN-MEDIATED IMMUNE RESPONSE BY CO-ADMINISTRATION WITH AN ANGIOGENESIS HIBITOR

USRE40911E1
(en)

1998-04-22
2009-09-08
Cornell Research Foundation, Inc.
Canine erythropoietin gene and recombinant protein

US6696411B1
(en)

1998-04-22
2004-02-24
Cornell Research Foundation, Inc.
Canine erythropoietin gene and recombinant protein

WO1999066054A2
(en)

1998-06-15
1999-12-23
Genzyme Transgenics Corp.
Erythropoietin analog-human serum albumin fusion protein

US20050181482A1
(en)

2004-02-12
2005-08-18
Meade Harry M.
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk

US6541033B1
(en)

1998-06-30
2003-04-01
Amgen Inc.
Thermosensitive biodegradable hydrogels for sustained delivery of leptin

JP2002521461A
(en)

1998-07-29
2002-07-16
インビトロゲン・コーポレーション

Regulated expression of recombinant proteins using RNA viruses

EP0984062A1
(en)

1998-09-04
2000-03-08
Cytos Biotechnology AG
Production of human erythropoietin

US6420339B1
(en)

1998-10-14
2002-07-16
Amgen Inc.
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

US6660843B1
(en)

1998-10-23
2003-12-09
Amgen Inc.
Modified peptides as therapeutic agents

US7304150B1
(en)

1998-10-23
2007-12-04
Amgen Inc.
Methods and compositions for the prevention and treatment of anemia

US6777205B1
(en)

1998-11-06
2004-08-17
Sterrenbeld Biotechnologie North America, Inc.
Host cells expressing recombinant human erythropoietin

BR9905867A
(en)

1998-11-06
2001-01-23
Bio Sidus S A

Recombinant human erythropoietin-producing cell line and the recombinant human erythropoietin produced by this cell

BR9917606A
(en)

1998-11-06
2002-12-31
Bio Sidus S A

Procedure for the purification of recombinant human erythropoietin from cell culture supernatants and recombinant human erythropoietin obtained with such procedure

BR9905868A
(en)

1998-11-06
2001-01-23
Bio Sidus S A

Mass culture procedure for mammalian cells to obtain recombinant human erythropoietin and recombinant human erythropoietin obtained with such procedure

DE19857609A1
(en)

1998-12-14
2000-06-15
Hannelore Ehrenreich

Use of erythropoietin for the treatment of human cerebral ischemia

US6245740B1
(en)

1998-12-23
2001-06-12
Amgen Inc.
Polyol:oil suspensions for the sustained release of proteins

US6451346B1
(en)

1998-12-23
2002-09-17
Amgen Inc
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents

DE19905501B4
(en)

1999-02-10
2005-05-19
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie

A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament

US7345019B1
(en)

1999-04-13
2008-03-18
The Kenneth S. Warren Institute, Inc.
Modulation of excitable tissue function by peripherally administered erythropoietin

US7410941B1
(en)

1999-04-13
2008-08-12
The Kenneth S. Warren Institute, Inc.
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin

US7604960B2
(en)

1999-04-15
2009-10-20
Crucell Holland B.V.
Transient protein expression methods

US7297680B2
(en)

1999-04-15
2007-11-20
Crucell Holland B.V.
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content

US6855544B1
(en)

1999-04-15
2005-02-15
Crucell Holland B.V.
Recombinant protein production in a human cell

US20050170463A1
(en)

1999-04-15
2005-08-04
Abraham Bout
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins

US8236561B2
(en)

1999-04-15
2012-08-07
Crucell Holland B.V.
Efficient production of IgA in recombinant mammalian cells

US20050164386A1
(en)

1999-04-15
2005-07-28
Uytdehaag Alphonsus G.
Overexpression of enzymes involved in post-translational protein modifications in human cells

EP1177285A1
(en)

1999-05-07
2002-02-06
Genentech, Inc.
Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same

US6831060B2
(en)

1999-05-07
2004-12-14
Genentech, Inc.
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same

US6555343B1
(en)

1999-05-07
2003-04-29
Genentech Inc.
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same

AT409379B
(en)

1999-06-02
2002-07-25
Baxter Ag

MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE

US7067110B1
(en)

1999-07-21
2006-06-27
Emd Lexigen Research Center Corp.
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens

SK782002A3
(en)

1999-07-21
2003-08-05
Lexigen Pharm Corp
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens

US6737519B1
(en)

1999-07-30
2004-05-18
Genome Therapeutics Corporation
Human genes relating to respiratory diseases and obesity

US8106098B2
(en)

1999-08-09
2012-01-31
The General Hospital Corporation
Protein conjugates with a water-soluble biocompatible, biodegradable polymer

DE60025832T2
(en)

1999-08-09
2006-08-31
Emd Lexigen Research Center Corp., Billerica

MULTIPLE CYTOKINE ANTIBODIES COMPLEX

AU2154401A
(en)

1999-11-12
2001-05-30
Merck Patent Gmbh
Erythropoietin forms with improved properties

US20050202538A1
(en)

1999-11-12
2005-09-15
Merck Patent Gmbh
Fc-erythropoietin fusion protein with improved pharmacokinetics

US6703480B1
(en)

1999-11-24
2004-03-09
Palani Balu
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use

US7521220B2
(en)

1999-11-26
2009-04-21
Crucell Holland B.V.
Production of vaccines

US7192759B1
(en)

1999-11-26
2007-03-20
Crucell Holland B.V.
Production of vaccines

US7527961B2
(en)

1999-11-26
2009-05-05
Crucell Holland B.V.
Production of vaccines

AU1647501A
(en)

1999-12-10
2001-06-18
Cytos Biotechnology Ag
Replicon based activation of endogenous genes

DE60122286T2
(en)

2000-02-11
2007-08-02
Merck Patent Gmbh

INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS

WO2001079480A1
(en)

2000-04-12
2001-10-25
Human Genome Sciences, Inc.
Albumin fusion proteins

US20050100991A1
(en)

2001-04-12
2005-05-12
Human Genome Sciences, Inc.
Albumin fusion proteins

IES20010462A2
(en)

2000-05-12
2001-11-14
Cyril John Higgins
Use of the world wide web

WO2002002143A2
(en)

2000-06-29
2002-01-10
Lexigen Pharmaceuticals Corp.
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents

CA2415713A1
(en)

2000-07-13
2002-01-24
Invitrogen Corporation
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix

US7622503B2
(en)

2000-08-24
2009-11-24
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof

US7919647B2
(en)

2000-08-24
2011-04-05
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof

US7855229B2
(en)

2000-08-24
2010-12-21
University Of Tennessee Research Foundation
Treating wasting disorders with selective androgen receptor modulators

US7645898B2
(en)

2000-08-24
2010-01-12
University Of Tennessee Research Foundation
Selective androgen receptor modulators and method of use thereof

EP1326969B1
(en)

2000-09-25
2009-04-15
Genetronics, Inc.
Improved system for regulation of transgene expression

US7087224B2
(en)

2000-10-31
2006-08-08
Amgen Inc.
Method of treating anemia by administering IL-1ra

AU2002233230B2
(en)

2000-12-20
2007-02-01
F. Hoffmann-La Roche Ag
Erythropoietin conjugates

US20030072737A1
(en)

2000-12-29
2003-04-17
Michael Brines
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

US7767643B2
(en)

2000-12-29
2010-08-03
The Kenneth S. Warren Institute, Inc.
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs

US6531121B2
(en)

2000-12-29
2003-03-11
The Kenneth S. Warren Institute, Inc.
Protection and enhancement of erythropoietin-responsive cells, tissues and organs

KR100399337B1
(en)

2001-02-07
2003-09-26
드림바이오젠 주식회사
Method for Cell-free Protein Post-translational Modification

WO2002072605A2
(en)

2001-03-07
2002-09-19
Merck Patent Gmbh
Expression technology for proteins containing a hybrid isotype antibody moiety

DE10112825A1
(en)

2001-03-16
2002-10-02
Fresenius Kabi De Gmbh

HESylation of active ingredients in aqueous solution

US6992174B2
(en)

2001-03-30
2006-01-31
Emd Lexigen Research Center Corp.
Reducing the immunogenicity of fusion proteins

EP1383785B1
(en)

2001-05-03
2011-03-16
Merck Patent GmbH
Recombinant tumor specific antibody and use thereof

US20030143191A1
(en)

2001-05-25
2003-07-31
Adam Bell
Chemokine beta-1 fusion proteins

EP1421104A4
(en)

2001-08-02
2005-08-24
Trinity Biomedical Technology
Human zona pellucida proteins and methods of their use in diagnosing male infertility

US20030104996A1
(en)

2001-08-30
2003-06-05
Tiansheng Li
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations

AU2002325712C1
(en)

2001-08-30
2008-07-31
Stem Cell Therapeutics Inc.
Differentiation of neural stem cells and therapeutic use theeof

CA2460184A1
(en)

2001-09-14
2003-03-27
Stem Cell Therapeutics Inc.
Prolactin induced increase in neural stem cell numbers and therapeutical use thereof

AR036402A1
(en)

2001-09-18
2004-09-08
Stem Cell Therapeutics Inc

EFFECT OF GROWTH HORMONE AND IGF-1 ON NEURONAL MOTHER CELLS.

CA2466881A1
(en)

2001-11-28
2003-06-05
Sandoz Gmbh
Cell culture process

BR0214650A
(en)

2001-12-04
2005-05-03
Merck Patent Gmbh

Modulated selectivity immunocytokines

US20070161608A1
(en)

2001-12-06
2007-07-12
Dalton James T
Selective androgen receptor modulators for treating muscle wasting

US8853266B2
(en)

2001-12-06
2014-10-07
University Of Tennessee Research Foundation
Selective androgen receptor modulators for treating diabetes

NZ533124A
(en)

2001-12-07
2005-11-25
Crucell Holland B
Production of viruses, viral isolates and vaccines

WO2005003296A2
(en)

2003-01-22
2005-01-13
Human Genome Sciences, Inc.
Albumin fusion proteins

AU2002364587A1
(en)

2001-12-21
2003-07-30
Human Genome Sciences, Inc.
Albumin fusion proteins

AU2002364586A1
(en)

2001-12-21
2003-07-30
Delta Biotechnology Limited
Albumin fusion proteins

KR101032589B1
(en)

2002-01-17
2011-05-06
론자 바이올로직스 피엘씨
Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium

DE10209821A1
(en)

2002-03-06
2003-09-25
Biotechnologie Ges Mittelhesse

Coupling of proteins to a modified polysaccharide

DE10209822A1
(en)

2002-03-06
2003-09-25
Biotechnologie Ges Mittelhesse

Coupling of low molecular weight substances to a modified polysaccharide

US20030191056A1
(en)

2002-04-04
2003-10-09
Kenneth Walker
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins

WO2003094858A2
(en)

2002-05-13
2003-11-20
Modigenetech Ltd.
Ctp-extended erythropoietin

NZ537306A
(en)

2002-07-01
2008-11-28
Kenneth S Warren Inst Inc
Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier

ES2398706T3
(en)

2002-07-09
2013-03-21
Baxter International Inc.

Animal protein free medium for cell culture

DE10234192B4
(en)

2002-07-26
2009-11-26
Epoplus Gmbh Co.Kg

Use of erythropoietin

AU2003250705A1
(en)

2002-07-31
2004-02-16
Stem Cell Therapeutics Inc.
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)

US7344858B2
(en)

2002-08-31
2008-03-18
Cj Corp
Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform

ES2343518T3
(en)

2002-09-09
2010-08-03
Hanall Biopharma Co., Ltd.

ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT.

DE20321793U1
(en)

2002-09-11
2010-06-02
Fresenius Kabi Deutschland Gmbh

Hydroxyalkyl starch derivatives

RU2329274C2
(en)

2002-09-11
2008-07-20
Фрезениус Каби Дойчланд Гмбх
Method of obtaining derivatives of hydroxyalkyl starch

EP1681303B1
(en)

2002-09-11
2013-09-04
Fresenius Kabi Deutschland GmbH
HASylated polypeptides, especially HASylated erythropoietin

US7538092B2
(en)

2002-10-08
2009-05-26
Fresenius Kabi Deutschland Gmbh
Pharmaceutically active oligosaccharide conjugates

KR101086660B1
(en)

2002-12-17
2011-11-24
메르크 파텐트 게엠베하
Humanized antibody h14.18 of the mouse 14.18 antibody binding to gd2 and its fusion with il-2

BRPI0406995A
(en)

2003-02-03
2006-01-10
Japan Immuno Inc

High expression vector for animal cells

US8084424B2
(en)

2003-04-09
2011-12-27
University Of Utah Research Foundation
Compositions and methods related to erythropoietin

US7459152B2
(en)

2003-04-23
2008-12-02
Rush University Medical Center
Erythropoietin administration to improve graft survival

EP1623023B1
(en)

2003-05-09
2008-11-12
Crucell Holland B.V.
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom

ES2395413T3
(en)

2003-05-12
2013-02-12
Affymax, Inc.

Peptides that bind to the erythropoietin receptor

JP2007530440A
(en)

2003-05-12
2007-11-01
アフィーマックス・インコーポレイテッド

Novel poly (ethylene glycol) modified compounds and uses thereof

DE602004020610D1
(en)

2003-05-12
2009-05-28
Affymax Inc

NEW PEPTIDE BINDING TO THE ERYTHROPOIETIN RECEPTOR

BRPI0411166A
(en)

2003-05-12
2006-07-18
Affymax Inc

compound comprising a peptide moiety, a spacer moiety and a water soluble polymer moiety and a pharmaceutical composition comprising such a compound

EP1626992B1
(en)

2003-05-23
2010-06-02
Crucell Holland B.V.
Production of recombinant igm in per.c6 cells

NZ543859A
(en)

2003-06-10
2008-01-31
Lg Life Sciences Ltd
Aqueous formulation that has storage stability over a long period without serum albumin comprising human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers

EP1660631B1
(en)

2003-08-01
2013-04-24
Life Technologies Corporation
Compositions and methods for purifying short rna molecules

WO2005014655A2
(en)

2003-08-08
2005-02-17
Fresenius Kabi Deutschland Gmbh
Conjugates of hydroxyalkyl starch and a protein

AU2004277954A1
(en)

2003-09-29
2005-04-14
The Kenneth S Warren Institute, Inc.
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

WO2005067889A1
(en)

2003-12-30
2005-07-28
Durect Corporation
Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh

EP2233150B1
(en)

2003-12-30
2016-09-07
Augustinus Bader
Erythropoietin for use in the treatment of wounds or the transplantation of cells

AU2004309063B2
(en)

2003-12-31
2010-10-28
Merck Patent Gmbh
Fc-erythropoietin fusion protein with improved pharmacokinetics

DE102004004509B4
(en)

2004-01-23
2010-07-01
Epoplus Gmbh Co.Kg

Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage

EP1740202B1
(en)

2004-02-13
2012-05-09
Stem Cell Therapeutics Corp.
Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis

US7255288B2
(en)

2004-03-08
2007-08-14
Wan Shan Chan
Aroma therapy for fountain

CN1946742A
(en)

2004-03-11
2007-04-11
弗雷泽纽斯卡比德国有限公司
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination

CN102302787A
(en)

2004-03-11
2012-01-04
费森尤斯卡比德国有限公司
Conjugates of hydroxyalkyl starch and a protein

US7588745B2
(en)

2004-04-13
2009-09-15
Si Options, Llc
Silicon-containing products

US20110237664A1
(en)

2004-06-07
2011-09-29
Dalton James T
Selective androgen receptor modulators for treating diabetes

US9884038B2
(en)

2004-06-07
2018-02-06
University Of Tennessee Research Foundation
Selective androgen receptor modulator and methods of use thereof

US9889110B2
(en)

2004-06-07
2018-02-13
University Of Tennessee Research Foundation
Selective androgen receptor modulator for treating hormone-related conditions

WO2009100255A2
(en)

2008-02-08
2009-08-13
Ambrx, Inc.
Modified leptin polypeptides and their uses

US20060094104A1
(en)

2004-10-29
2006-05-04
Leopold Grillberger
Animal protein-free media for cultivation of cells

WO2006062685A2
(en)

2004-11-11
2006-06-15
Affymax, Inc.
Novel peptides that bind to the erythropoietin receptor

WO2006060148A2
(en)

2004-11-11
2006-06-08
Affymax, Inc.
Novel peptides that bind to the erythropoietin receptor

WO2006061853A2
(en)

2004-12-10
2006-06-15
Serum Institute Of India Limited
Novel erythropoietic compounds and a process for producing erythropoietic compounds

EP1848461A2
(en)

2005-02-16
2007-10-31
Nektar Therapeutics Al, Corporation
Conjugates of an epo moiety and a polymer

US8324159B2
(en)

2005-06-03
2012-12-04
Affymax, Inc.
Erythropoietin receptor peptide formulations and uses

US7550433B2
(en)

2005-06-03
2009-06-23
Affymax, Inc.
Erythropoietin receptor peptide formulations and uses

US7919461B2
(en)

2005-06-03
2011-04-05
Affymax, Inc.
Erythropoietin receptor peptide formulations and uses

BRPI0617117A2
(en)

2005-08-31
2011-07-12
Univ Tennessee Res Foundation

treatment of kidney disease, burns, injuries and spinal cord damage with selective androgen receptor modulators

EP1762250A1
(en)

2005-09-12
2007-03-14
Fresenius Kabi Deutschland GmbH
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine

EP1928488A4
(en)

2005-09-27
2009-07-22
Stem Cell Therapeutics Corp
Oligodendrocyte precursor cell proliferation regulated by prolactin

WO2008048671A1
(en)

2006-10-18
2008-04-24
University Of Illinois
Embryonic-like stem cells derived from adult human peripheral blood and methods of use

US9388382B2
(en)

2005-10-05
2016-07-12
The Board Of Trustees Of The University Of Illinois
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells

WO2007060213A2
(en)

2005-11-24
2007-05-31
Laboratoires Serono S.A.
Erythropoietin polypeptides and uses thereof

EP2495308A1
(en)

2005-12-08
2012-09-05
Amgen Inc.
Improved production of glycoproteins using manganese

ES2629304T3
(en)

2006-01-04
2017-08-08
Baxalta Incorporated

Cell culture medium without oligopeptides

US7625564B2
(en)

2006-01-27
2009-12-01
Novagen Holding Corporation
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo

DE102006004008A1
(en)

2006-01-27
2007-08-02
Hannelore Prof. Dr. Dr. Ehrenreich
Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered

JP2009530234A
(en)

2006-03-17
2009-08-27
ステムセルセラピューティクスコーポレイション

Administration regimen for LH or HCG and EPO for the treatment of neurodegenerative diseases

US8546329B2
(en)

2006-03-22
2013-10-01
Chugai Seiyaku Kabushiki Kaisha
Erythropoietin solution preparation

CN101062407A
(en)

2006-04-29
2007-10-31
中国科学院上海生命科学研究院
Function of erythropoietin in the preventing and treating of retinal injury

EP3147278B1
(en)

2006-07-12
2020-02-12
University of Tennessee Research Foundation
Compound for treating breast cancer and progestin-dependent conditions

CN105820231A
(en)

2006-08-04
2016-08-03
普罗龙药品有限责任公司
Modified erythropoietin

CA2661054A1
(en)

2006-08-22
2008-02-28
Chugai Seiyaku Kabushiki Kaisha
Prophylactic and/or therapeutic agents for peripheral neuropathy

BRPI0714526A2
(en)

2006-08-24
2013-04-30
Univ Tennessee Res Foundation

substituted acylanilides and their methods of use

US8454948B2
(en)

2006-09-14
2013-06-04
Medgenics Medical Israel Ltd.
Long lasting drug formulations

AU2007294858B2
(en)

2006-09-14
2011-05-12
Medgenics Medical Israel, Ltd
Long lasting drug formulations

WO2008065372A2
(en)

2006-11-28
2008-06-05
Nautilus Biotech, S.A.
Modified erythropoietin polypeptides and uses thereof for treatment

EP2089424B1
(en)

2006-12-06
2015-07-01
JCR PHARMACEUTICALS Co., LTD.
Method for production of human erythropoietin

WO2008074851A2
(en)

2006-12-19
2008-06-26
Nokad
Method for inhibiting the expression of endogenous erythropoietin (epo)

JP2010517529A
(en)

2007-02-02
2010-05-27
アムジエン・インコーポレーテツド

Hepcidin and hepcidin antibody

AR065613A1
(en)

2007-03-09
2009-06-17
Chugai Pharmaceutical Co Ltd

PROTECTION AGENTS FOR TRANSPLANTED ORGANS

US20080260820A1
(en)

2007-04-19
2008-10-23
Gilles Borrelly
Oral dosage formulations of protease-resistant polypeptides

EP2167115A2
(en)

2007-06-15
2010-03-31
University Of Zurich
Treatment for alzheimer’s disease

WO2009010107A1
(en)

2007-07-19
2009-01-22
Hannelore Ehrenreich
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis

CA2720628A1
(en)

2007-07-26
2009-01-29
Novagen Holding Corporation
Fusion proteins having mutated immunoglobulin hinge region

US7968603B2
(en)

2007-09-11
2011-06-28
University Of Tennessee Research Foundation
Solid forms of selective androgen receptor modulators

WO2009043049A2
(en)

2007-09-27
2009-04-02
Amgen Inc.
Pharmaceutical formulations

EP3381445B1
(en)

2007-11-15
2023-10-25
Amgen Inc.
Aqueous formulation of antibody stablised by antioxidants for parenteral administration

EP2070950A1
(en)

2007-12-14
2009-06-17
Fresenius Kabi Deutschland GmbH
Hydroxyalkyl starch derivatives and process for their preparation

JP5701064B2
(en)

2008-01-25
2015-04-15
アムジエン・インコーポレーテツド

Ferroportin antibody and method of use thereof

EP2095829A1
(en)

2008-02-27
2009-09-02
LEK Pharmaceuticals D.D.
Selenium containing modifying agents and conjugates

US8653249B2
(en)

2008-02-27
2014-02-18
Fuso Pharmaceutical Industries, Ltd.
Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof

EP2620448A1
(en)

2008-05-01
2013-07-31
Amgen Inc.
Anti-hepcidin antibodies and methods of use

DE102008002210A1
(en)

2008-06-04
2009-12-10
Evonik Degussa Gmbh

Process for the fermentative production of erythropoietin

DE102008002209A1
(en)

2008-06-04
2009-12-10
Evonik Degussa Gmbh

Process for the purification of erythropoietin

US8003689B2
(en)

2008-06-20
2011-08-23
Gtx, Inc.
Metabolites of selective androgen receptor modulators and methods of use thereof

WO2010034442A1
(en)

2008-09-23
2010-04-01
F. Hoffmann-La Roche Ag
Purification of erythropoietin

US8278418B2
(en)

2008-09-26
2012-10-02
Ambrx, Inc.
Modified animal erythropoietin polypeptides and their uses

US8318167B2
(en)

2008-11-13
2012-11-27
The General Hospital Corporation
Methods and compositions for regulating iron homeostasis by modulation of BMP-6

DE102008054716A1
(en)

2008-12-16
2010-06-17
Evonik Degussa Gmbh

In-process control in a process for the production of EPO

DK2385115T3
(en)

2008-12-22
2015-11-30
Univ Hokkaido Nat Univ Corp
An expression vector for the production of a protein derived from a foreign gene in large quantities using animal cells as well as its use

US20100272816A1
(en)

2009-04-27
2010-10-28
Wolfgang Rudinger
Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient

MX356669B
(en)

2009-05-02
2018-06-08
Genzyme Corp
Gene therapy for neurodegenerative disorders.

US20120264688A1
(en)

2009-09-23
2012-10-18
Walter Hinderer
Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same

EP2490957B1
(en)

2009-10-23
2016-11-23
Amgen, Inc
Vial adapter and system

KR102513760B1
(en)

2010-06-07
2023-03-27
암젠 인크
Drug delivery device

CN103260649A
(en)

2010-06-15
2013-08-21
迈德詹尼克斯医疗以色列有限公司
Long lasting drug formulations

EA024507B1
(en)

2010-09-28
2016-09-30
Амилин Фармасьютикалс, Ллк
Highly soluble leptins

US9480624B2
(en)

2011-03-31
2016-11-01
Amgen Inc.
Vial adapter and system

PT2699293T
(en)

2011-04-20
2019-05-21
Amgen Inc
Autoinjector apparatus

EP3045188B1
(en)

2011-10-14
2020-12-23
Amgen Inc.
Injector and method of assembly

KR101443257B1
(en)

2011-10-18
2014-09-19
주식회사 종근당
Methods for Purifying Erythropoietin Analogs Having Lower Isoelectric Point

US10350139B2
(en)

2011-10-25
2019-07-16
Corning Incorporated
Pharmaceutical glass packaging assuring pharmaceutical sterility

WO2013063287A1
(en)

2011-10-25
2013-05-02
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9969683B2
(en)

2012-07-13
2018-05-15
Gtx, Inc.
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)

US9622992B2
(en)

2012-07-13
2017-04-18
Gtx, Inc.
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

US9744149B2
(en)

2012-07-13
2017-08-29
Gtx, Inc.
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

US10258596B2
(en)

2012-07-13
2019-04-16
Gtx, Inc.
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)

US10314807B2
(en)

2012-07-13
2019-06-11
Gtx, Inc.
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)

US10987334B2
(en)

2012-07-13
2021-04-27
University Of Tennessee Research Foundation
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)

ES2818915T3
(en)

2012-07-13
2021-04-14
Oncternal Therapeutics Inc

Method of treating breast cancers with a selective androgen receptor modulator (SARM)

US9650411B2
(en)

2012-08-07
2017-05-16
Kyowa Hakko Kirin Co., Ltd.
Method of purifying protein

CN104822826B
(en)

2012-10-15
2019-04-30
百时美施贵宝公司
The mammalian cell culture process generated for albumen

CA3206182A1
(en)

2012-11-21
2014-05-30
Amgen Inc.
Drug delivery device including insertion member and reservoir

EP2970351B1
(en)

2013-03-14
2017-09-13
Translate Bio, Inc.
Ribonucleic acids with 4′-thio-modified nucleotides and related methods

CN105263514B
(en)

2013-03-15
2019-04-26
本质生命科学有限公司
Anti- hepcidin antibody and application thereof

EP2970420A4
(en)

2013-03-15
2016-08-17
Apotex Inc
Enhanced liquid formulation stability of erythropoietin alpha through purification processing

CA2904725C
(en)

2013-03-15
2022-04-12
Amgen Inc.
Drug cassette, autoinjector, and autoinjector system

TWI639453B
(en)

2013-03-15
2018-11-01
美商安美基公司
Cassette for an injector

EP3831427A1
(en)

2013-03-22
2021-06-09
Amgen Inc.
Injector and method of assembly

US9717649B2
(en)

2013-04-24
2017-08-01
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9707153B2
(en)

2013-04-24
2017-07-18
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9700485B2
(en)

2013-04-24
2017-07-11
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9603775B2
(en)

2013-04-24
2017-03-28
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9849066B2
(en)

2013-04-24
2017-12-26
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9713572B2
(en)

2013-04-24
2017-07-25
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9707154B2
(en)

2013-04-24
2017-07-18
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9717648B2
(en)

2013-04-24
2017-08-01
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9700486B2
(en)

2013-04-24
2017-07-11
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9707155B2
(en)

2013-04-24
2017-07-18
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

US9839579B2
(en)

2013-04-24
2017-12-12
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

EP3036254A1
(en)

2013-08-20
2016-06-29
LEK Pharmaceuticals d.d.
Cell culture medium and process for controlling -amidation and/or c-terminal amino acid cleavage of polypeptides

US10758683B2
(en)

2013-10-24
2020-09-01
Amgen Inc.
Drug delivery system with temperature-sensitive control

EP3060144A1
(en)

2013-10-24
2016-08-31
Medgenics Medical Israel, Ltd
Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof

ES2744837T3
(en)

2013-10-24
2020-02-26
Amgen Inc

Injector and assembly procedure

US10994112B2
(en)

2014-02-05
2021-05-04
Amgen Inc.
Drug delivery system with electromagnetic field generator

SG10201811702TA
(en)

2014-05-07
2019-01-30
Amgen Inc
Autoinjector with shock reducing elements

SG11201609050UA
(en)

2014-05-30
2016-12-29
Pfizer
Carbonitrile derivatives as selective androgen receptor modulators

SG10201806528QA
(en)

2014-06-03
2018-08-30
Amgen Inc
Controllable drug delivery system and method of use

AU2015321462B2
(en)

2014-09-22
2020-04-30
Intrinsic Lifesciences Llc
Humanized anti-hepcidin antibodies and uses thereof

MX2017004836A
(en)

2014-10-14
2017-07-20
Amgen Inc
Drug injection device with visual and audio indicators.

JP2017538512A
(en)

2014-12-19
2017-12-28
アムジエン・インコーポレーテツド

Drug delivery device including live button or user interface field

EP3848072A1
(en)

2014-12-19
2021-07-14
Amgen Inc.
Drug delivery device with proximity sensor

JP6484345B2
(en)

2015-02-17
2019-03-20
アムジエン・インコーポレーテツド

Drug delivery device with fixation and / or return assisted by vacuum

ES2905870T3
(en)

2015-02-27
2022-04-12
Amgen Inc

Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard

WO2017039786A1
(en)

2015-09-02
2017-03-09
Amgen Inc.
Syringe assembly adapter for a syringe

WO2017068051A1
(en)

2015-10-21
2017-04-27
Lek Pharmaceuticals D.D.
Peg-based dendron and process for producing the same

ES2755717T3
(en)

2015-12-09
2020-04-23
Amgen Inc

Autoinjector with signaling cap

US11154661B2
(en)

2016-01-06
2021-10-26
Amgen Inc.
Auto-injector with signaling electronics

EP3429663B1
(en)

2016-03-15
2020-07-15
Amgen Inc.
Reducing probability of glass breakage in drug delivery devices

US11541168B2
(en)

2016-04-29
2023-01-03
Amgen Inc.
Drug delivery device with messaging label

US11389588B2
(en)

2016-05-02
2022-07-19
Amgen Inc.
Syringe adapter and guide for filling an on-body injector

WO2017197222A1
(en)

2016-05-13
2017-11-16
Amgen Inc.
Vial sleeve assembly

US11238150B2
(en)

2016-05-16
2022-02-01
Amgen Inc.
Data encryption in medical devices with limited computational capability

EP3465124A1
(en)

2016-06-03
2019-04-10
Amgen Inc.
Impact testing apparatuses and methods for drug delivery devices

WO2018004842A1
(en)

2016-07-01
2018-01-04
Amgen Inc.
Drug delivery device having minimized risk of component fracture upon impact events

WO2018034784A1
(en)

2016-08-17
2018-02-22
Amgen Inc.
Drug delivery device with placement detection

US20200261643A1
(en)

2016-10-25
2020-08-20
Amgen Inc.
On-body injector

WO2018136398A1
(en)

2017-01-17
2018-07-26
Amgen Inc.
Injection devices and related methods of use and assembly

EP3582825A1
(en)

2017-02-17
2019-12-25
Amgen Inc.
Drug delivery device with sterile fluid flowpath and related method of assembly

US11369736B2
(en)

2017-02-17
2022-06-28
Amgen Inc.
Cannula insertion and retraction mechanisms

WO2018165143A1
(en)

2017-03-06
2018-09-13
Amgen Inc.
Drug delivery device with activation prevention feature

US11571511B2
(en)

2017-03-07
2023-02-07
Amgen Inc.
Insertion mechanism and method of inserting a needle of a drug delivery device

US20200023122A1
(en)

2017-03-09
2020-01-23
Amgen Inc.
Insertion mechanism for drug delivery device

EP3570871B1
(en)

2017-03-20
2020-11-18
H. Hoffnabb-La Roche Ag
Method for in vitro glycoengineering of an erythropoiesis stimulating protein

MX2019011416A
(en)

2017-03-28
2019-11-01
Amgen Inc
Plunger rod and syringe assembly system and method.

WO2018226565A1
(en)

2017-06-08
2018-12-13
Amgen Inc.
Torque driven drug delivery device

US11590294B2
(en)

2017-06-08
2023-02-28
Amgen Inc.
Syringe assembly for a drug delivery device and method of assembly

KR102268647B1
(en)

2017-06-12
2021-06-23
한국코러스 주식회사
A Composition comprising erythropoietin and a method of producing the same

AU2018288604A1
(en)

2017-06-22
2019-11-21
Amgen Inc.
Device activation impact/shock reduction

JP2020525059A
(en)

2017-06-23
2020-08-27
アムジエン・インコーポレーテツド

Electronic drug delivery device including a cap activated by a switch assembly

JP2020527373A
(en)

2017-07-14
2020-09-10
アムジエン・インコーポレーテツド

Needle insertion retreat system with double torsion spring system

EP3655063A1
(en)

2017-07-21
2020-05-27
Amgen Inc.
Gas permeable sealing member for drug container and methods of assembly

EP3658206A1
(en)

2017-07-25
2020-06-03
Amgen Inc.
Drug delivery device with container access system and related method of assembly

MA49677A
(en)

2017-07-25
2021-04-21
Amgen Inc

DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS

MA49838A
(en)

2017-08-09
2020-06-17
Amgen Inc

DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE

MA49897A
(en)

2017-08-18
2020-06-24
Amgen Inc

ON-BODY INJECTOR WITH STERILE ADHESIVE PATCH

US11103636B2
(en)

2017-08-22
2021-08-31
Amgen Inc.
Needle insertion mechanism for drug delivery device

WO2019070472A1
(en)

2017-10-04
2019-04-11
Amgen Inc.
Flow adapter for drug delivery device

CN111132711B
(en)

2017-10-06
2022-07-01
安进公司
Drug delivery device with interlocking components and related assembly methods

WO2019074579A1
(en)

2017-10-09
2019-04-18
Amgen Inc.
Drug delivery device with drive assembly and related method of assembly

MA50528A
(en)

2017-11-03
2020-09-09
Amgen Inc

SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE

EP3707075A1
(en)

2017-11-06
2020-09-16
Amgen Inc.
Fill-finish assemblies and related methods

US20200261648A1
(en)

2017-11-06
2020-08-20
Amgen Inc.
Drug delivery device with placement and flow sensing

US11191904B2
(en)

2017-11-10
2021-12-07
Amgen Inc.
Plungers for drug delivery devices

CA3084486A1
(en)

2017-11-16
2019-05-23
Amgen Inc.
Autoinjector with stall and end point detection

CA3079540A1
(en)

2017-11-16
2019-05-23
Amgen Inc.
Door latch mechanism for drug delivery device

EP3805396A4
(en)

2018-05-24
2022-03-23
National University Corporation Hokkaido University
Novel vector and use thereof

US10835685B2
(en)

2018-05-30
2020-11-17
Amgen Inc.
Thermal spring release mechanism for a drug delivery device

US11083840B2
(en)

2018-06-01
2021-08-10
Amgen Inc.
Modular fluid path assemblies for drug delivery devices

WO2020023336A1
(en)

2018-07-24
2020-01-30
Amgen Inc.
Hybrid drug delivery devices with grip portion

CN112351804A
(en)

2018-07-24
2021-02-09
安进公司
Delivery device for administering a drug

CN112469454A
(en)

2018-07-24
2021-03-09
安进公司
Delivery device for administering a drug

US20210260279A1
(en)

2018-07-24
2021-08-26
Amgen Inc.
Hybrid drug delivery devices with optional grip portion and related method of preparation

MA53320A
(en)

2018-07-31
2021-11-03
Amgen Inc

FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE

US20210346601A1
(en)

2018-09-24
2021-11-11
Amgen Inc.
Interventional dosing systems and methods

WO2020068476A1
(en)

2018-09-28
2020-04-02
Amgen Inc.
Muscle wire escapement activation assembly for a drug delivery device

JP2022503983A
(en)

2018-10-02
2022-01-12
アムジエン・インコーポレーテツド

Injection system for drug delivery with internal force transmission

CA3112214A1
(en)

2018-10-05
2020-04-09
Amgen Inc.
Drug delivery device having dose indicator

BR112021007016A2
(en)

2018-10-15
2021-07-13
Amgen Inc.

drug delivery device having damping mechanism

US20210346596A1
(en)

2018-10-15
2021-11-11
Amgen Inc.
Platform assembly process for drug delivery device

WO2020091956A1
(en)

2018-11-01
2020-05-07
Amgen Inc.
Drug delivery devices with partial drug delivery member retraction

TW202100191A
(en)

2018-11-01
2021-01-01
美商安進公司
Drug delivery devices with partial needle retraction

CA3113076A1
(en)

2018-11-01
2020-05-07
Amgen Inc.
Drug delivery devices with partial drug delivery member retraction

JP2022529319A
(en)

2019-04-24
2022-06-21
アムジエン・インコーポレーテツド

Syringe sterility confirmation assembly and method

US20220273887A1
(en)

2019-08-23
2022-09-01
Amgen Inc.
Drug delivery device with configurable needle shield engagement components and related methods

WO2022159414A1
(en)

2021-01-22
2022-07-28
University Of Rochester
Erythropoietin for gastroinfestinal dysfunction

CA3217207A1
(en)

2021-05-21
2022-11-24
Amgen Inc.
Method of optimizing a filling recipe for a drug container

WO2023275715A1
(en)

2021-06-30
2023-01-05
Pfizer Inc.
Metabolites of selective androgen receptor modulators

WO2023209074A1
(en)

2022-04-28
2023-11-02
Institut National de la Santé et de la Recherche Médicale
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing

Family Cites Families (46)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3033753A
(en)

1959-08-31
1962-05-08
Wilfrid F White
Erythropoietic factor purification

US3865801A
(en)

1973-06-15
1975-02-11
Atomic Energy Commission
Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol

US4237224A
(en)

1974-11-04
1980-12-02
Board Of Trustees Of The Leland Stanford Jr. University
Process for producing biologically functional molecular chimeras

US4468464A
(en)

1974-11-04
1984-08-28
The Board Of Trustees Of The Leland Stanford Junior University
Biologically functional molecular chimeras

US4264731A
(en)

1977-05-27
1981-04-28
The Regents Of The University Of California
DNA Joining method

JPS5455790A
(en)

1977-10-05
1979-05-04
Tomoyuki Tajima
Production of erythropoetin

US4254095A
(en)

1978-04-27
1981-03-03
Research Corporation
Radioimmunoassay for erythropoietin

US4411994A
(en)

1978-06-08
1983-10-25
The President And Fellows Of Harvard College
Protein synthesis

US4273875A
(en)

1979-03-05
1981-06-16
The Upjohn Company
Plasmid and process of isolating same

US4293652A
(en)

1979-05-25
1981-10-06
Cetus Corporation
Method for synthesizing DNA sequentially

JPS5653696A
(en)

1979-10-09
1981-05-13
Ajinomoto Co Inc
Isolation of erythropoietin by adsorption

US4399216A
(en)

1980-02-25
1983-08-16
The Trustees Of Columbia University
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials

US4338397A
(en)

1980-04-11
1982-07-06
President And Fellows Of Harvard College
Mature protein synthesis

JPS6045849B2
(en)

1980-08-25
1985-10-12
林原健

Method for producing human erythropoietin

US4568448A
(en)

1980-11-26
1986-02-04
Mobil Oil Corporation
Hydrodesulfurization process employing poison-resistant catalyst

US4358535A
(en)

1980-12-08
1982-11-09
Board Of Regents Of The University Of Washington
Specific DNA probes in diagnostic microbiology

US4503151A
(en)

1980-12-10
1985-03-05
Research Corporation
Recombinant cDNA construction method and hybrid nucleotides useful in cloning

US4394443A
(en)

1980-12-18
1983-07-19
Yale University
Method for cloning genes

JPS57149228A
(en)

1981-03-11
1982-09-14
Ajinomoto Co Inc
Novel erythropoietin and its preparation

CA1190838A
(en)

1981-07-17
1985-07-23
Cavit Akin
Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer

CA1180647A
(en)

1981-07-17
1985-01-08
Cavit Akin
Light-emitting polynucleotide hybridization diagnostic method

US4442205A
(en)

1981-09-22
1984-04-10
The United States Of America As Represented By The Department Of Health And Human Services
Simian virus recombinant that directs the synthesis of hepatitis B surface antigen

AU561343B2
(en)

1981-10-19
1987-05-07
Genentech Inc.
Human immune interferon by recombinant dna

GR79202B
(en)

1982-05-05
1984-10-22
Genentech Inc

US6936694B1
(en)

1982-05-06
2005-08-30
Intermune, Inc.
Manufacture and expression of large structural genes

US4558005A
(en)

1982-09-13
1985-12-10
University Patents, Inc.
Monoclonal anti-erythropoietin

AU572108B2
(en)

1983-01-19
1988-05-05
Genentech Inc.
Human tpa production using vectors coding for dhfr protein

AU2353384A
(en)

1983-01-19
1984-07-26
Genentech Inc.
Amplification in eukaryotic host cells

US4713339A
(en)

1983-01-19
1987-12-15
Genentech, Inc.
Polycistronic expression vector construction

US4558006A
(en)

1983-02-04
1985-12-10
Kirin-Amgen, Inc.
A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin

JPH0686480B2
(en)

1983-02-21
1994-11-02
雪印乳業株式会社

Monoclonal antibody for erythropoietin production

WO1984004330A1
(en)

1983-04-22
1984-11-08
Amgen
Secretion of exogenous polypeptides from yeast

US4710473A
(en)

1983-08-10
1987-12-01
Amgen, Inc.
DNA plasmids

JPS6043395A
(en)

1983-08-19
1985-03-07
Sumitomo Chem Co Ltd
Preparation of erythropoietin

US4695542A
(en)

1983-10-04
1987-09-22
Dnax Research Institute Of Molecular And Cellular Biology, Inc.
cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity

US4757006A
(en)

1983-10-28
1988-07-12
Genetics Institute, Inc.
Human factor VIII:C gene and recombinant methods for production

JPH07106156B2
(en)

1983-10-28
1995-11-15
ジェネティックス、インスティチュ−ト

Manufacture of factor-VIII and related products

US4703008A
(en)

1983-12-13
1987-10-27
Kiren-Amgen, Inc.
DNA sequences encoding erythropoietin

IT1185503B
(en)

1984-01-11
1987-11-12
Univ New York

HUMAN Erythropietine ODNA CLONES

US4568488A
(en)

1984-01-11
1986-02-04
Lee Huang Sylvia
Reverse immunoaffinity chromatography purification method

GB8407498D0
(en)

1984-03-22
1984-05-02
Biogen Nv
High copy number expression vectors

JPS60215632A
(en)

1984-04-12
1985-10-29
Japan Found Cancer
Preparation of erythropoietin

IL77081A
(en)

1984-12-04
1999-10-28
Genetics Inst
Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin

US4677195A
(en)

1985-01-11
1987-06-30
Genetics Institute, Inc.
Method for the purification of erythropoietin and erythropoietin compositions

US4667016A
(en)

1985-06-20
1987-05-19
Kirin-Amgen, Inc.
Erythropoietin purification

JP3344027B2
(en)

1993-09-21
2002-11-11
ソニー株式会社

Dry etching method

1984

1984-12-10
NZ
NZ210501A
patent/NZ210501A/en
unknown

1984-12-11
WO
PCT/US1984/002021
patent/WO1985002610A1/en
unknown

1984-12-11
IL
IL73785A
patent/IL73785A/en
unknown

1984-12-12
ES
ES538519A
patent/ES8802329A1/en
not_active
Expired

1984-12-12
DE
DE8484308654T
patent/DE3482828D1/en
not_active
Expired – Lifetime

1984-12-12
EP
EP84308654A
patent/EP0148605B2/en
not_active
Expired – Lifetime

1984-12-12
CA
CA000616898A
patent/CA1339047C/en
not_active
Expired – Lifetime

1987

1987-10-23
US
US07/113,179
patent/US5441868A/en
not_active
Expired – Lifetime

1987-12-04
JP
JP62307341A
patent/JPH0655136B2/en
not_active
Expired – Lifetime

1990

1990-06-15
AU
AU57504/90A
patent/AU5750490A/en
not_active
Abandoned

1990-11-21
JP
JP2317592A
patent/JPH03198792A/en
active
Granted

1990-11-21
JP
JP2317593A
patent/JP2655750B2/en
not_active
Expired – Lifetime

1991

1991-11-04
SG
SG928/91A
patent/SG92891G/en
unknown

1992

1992-06-26
MX
MX9203598A
patent/MX9203598A/en
active
IP Right Grant

1992-07-20
AU
AU20421/92A
patent/AU657555B2/en
not_active
Expired

1993

1993-03-11
HK
HK200/93A
patent/HK20093A/en
not_active
IP Right Cessation

1993-05-14
CY
CY1643A
patent/CY1643A/en
unknown

1993-06-21
JP
JP5149531A
patent/JPH0776239B2/en
not_active
Expired – Lifetime

1993-07-01
NL
NL930128C
patent/NL930128I1/en
unknown

1993-12-23
AU
AU52722/93A
patent/AU5272293A/en
not_active
Abandoned

1995

1995-01-06
AU
AU10074/95A
patent/AU1007495A/en
not_active
Abandoned

1995-06-06
US
US08/468,369
patent/US5756349A/en
not_active
Expired – Lifetime

1995-06-06
US
US08/468,381
patent/US5618698A/en
not_active
Expired – Lifetime

1996

1996-03-29
JP
JP8076540A
patent/JP2708099B2/en
not_active
Expired – Lifetime

1997

1997-07-03
JP
JP9178411A
patent/JP2957974B2/en
not_active
Expired – Lifetime

1997-08-04
JP
JP9209391A
patent/JP3017962B2/en
not_active
Expired – Lifetime

1997-08-29
AU
AU36125/97A
patent/AU3612597A/en
not_active
Abandoned

1998

1998-12-16
JP
JP35799598A
patent/JP3276933B2/en
not_active
Expired – Lifetime

2001

2001-06-07
JP
JP2001173139A
patent/JP3375614B2/en
not_active
Expired – Lifetime

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU646822B2
(en)

1989-10-13
1994-03-10
Kirin-Amgen Inc.
Erythropoietin isoforms

Also Published As

Publication number
Publication date

MX9203598A
(en)

1992-09-01

JPH0655136B2
(en)

1994-07-27

CY1643A
(en)

1993-05-14

AU5272293A
(en)

1994-03-24

ES538519A0
(en)

1988-05-01

DE3482828D1
(en)

1990-08-30

US5756349A
(en)

1998-05-26

AU600650B2
(en)

1990-08-23

JPH03198792A
(en)

1991-08-29

JPH1095799A
(en)

1998-04-14

JP2957974B2
(en)

1999-10-06

IL73785A
(en)

1992-11-15

JP2655750B2
(en)

1997-09-24

JPS6455190A
(en)

1989-03-02

EP0148605A2
(en)

1985-07-17

EP0148605B2
(en)

1998-12-23

EP0148605B1
(en)

1990-07-25

JP2002045191A
(en)

2002-02-12

AU1007495A
(en)

1995-04-06

WO1985002610A1
(en)

1985-06-20

NZ210501A
(en)

1991-08-27

JP3276933B2
(en)

2002-04-22

JPH08269096A
(en)

1996-10-15

ES8802329A1
(en)

1988-05-01

JPH03259098A
(en)

1991-11-19

JP3017962B2
(en)

2000-03-13

US5618698A
(en)

1997-04-08

AU3612597A
(en)

1997-12-18

AU2042192A
(en)

1992-10-08

EP0148605A3
(en)

1987-06-03

NL930128I1
(en)

1993-11-01

JPH1072366A
(en)

1998-03-17

US5441868A
(en)

1995-08-15

JP3375614B2
(en)

2003-02-10

JPH0693000A
(en)

1994-04-05

JPH0776239B2
(en)

1995-08-16

JPH0435159B2
(en)

1992-06-10

AU657555B2
(en)

1995-03-16

CA1339047C
(en)

1997-05-27

HK20093A
(en)

1993-03-19

IL73785A0
(en)

1985-03-31

AU3746785A
(en)

1985-06-26

JP2708099B2
(en)

1998-02-04

JPH11253188A
(en)

1999-09-21

SG92891G
(en)

1992-02-14

Contact information